Journal Mobile Options
Table of Contents
Vol. 43, No. 4, 2001
Issue release date: May 2001
Neuropsychobiology 2001;43:273–276

Short-Term Rivastigmine Treatment Reduces EEG Slow-Wave Power in Alzheimer Patients

Adler G. · Brassen S.
Day Clinic for the Elderly and Clinical Neurophysiology Service, Central Institute of Mental Health, Mannheim, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


The effects of a 5-day treatment with rivastigmine on the resting EEG power spectrum were studied in 15 mildly to moderately ill Alzheimer patients. In these patients, beta power was positively correlated with cognitive performance and negatively correlated with functional impairment. Rivastigmine produced a decrease in delta and theta power with no effect of hemisphere and electrode position. Delta power decrease reflects the cerebral cholinergic action of rivastigmine and may thus allow a quantitative assessment of its CNS effects.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Brenner RP, Ulrich RF, Spiker DG, Scabassi RJ, Reynolds CF, Marin RS, Boller F: Computerized EEG spectral analysis in elderly normal, demented and depressed subjects. Electroencephalogr Clin Neurophysiol 1986;64:483–492.
  2. Breslau J, Starr A, Sicotte N, Buchsbaum MS: Topographic EEG changes with normal aging and SDAT. Electroencephalogr Clin Neurophysiol 1989;72:281–289.
  3. Chiaramonti R, Muscas GC, Paganini M, Müller TJ, Fallgatter AJ, Versari A, Strik WK: Correlations of topographical EEG feature with clinical severity in mild and moderate dementia of Alzheimer type. Neuropsychobiology 1997;36:153–158.
  4. Coben LA, Danzinger WL, Berg L: Frequency analysis of the resting awake EEG in mild senile dementia of Alzheimer type. Electroencephalogr Clin Neurophysiol 1983;55:372–380.
  5. Duffy FH, Albert MS, McAnulty G: Brain electrical activity in patients with presenile and senile dementia of the Alzheimer type. Ann Neurol 1984;16:439–448.
  6. Förstl H, Besthorn C, Sattel H, Zerfass R, Geiger-Kabisch C, Schreiter-Gasser U, Hentschel F: Volumetrische Hinrveränderungen und quantitatives EEG bei normalem Altern und Alzheimer-Demenz. Nervenarzt 1996;67:53–61.
  7. Giannitrapani D, Collins J, Vassiliadis D: The EEG spectra of Alzheimer’s disease. Int J Psychophysiol 1991;10:259–269.
  8. Jelic V, Shigeta M, Julin P, Almkvist O, Winblad B, Wahlund L-O: Quantitative electroencephalography power and coherence in Alzheimer’s disease and mild cognitive impairment. Dementia 1996;7:314–323.
  9. d’Onofrio F, Salvia S, Petretta V, Bonavita V, Rodriguez G, Tedeschi G: Quantified-EEG in normal aging and dementias. Acta Neurol Scand 1996;93:336–345.
  10. Penttila M, Partanen VJ, Soininen H, Riekkinen PJ: Quantitative analysis of occipital EEG in different stages of Alzheimer’s disease. Electroencephalogr Clin Neurophysiol 1985;60:1–6.
  11. Szelies B, Grond M, Herholz K, Kessler J, Heiss WD: Quantitative EEG mapping and PET in Alzheimer’s disease. J Neurol Sci 1992;110:46–56.
  12. Dustman RE, LaMarche JA, Cohn NB, Shearer DE, Talone JM: Power spectral analysis and cortical coupling of EEG for young and old normal adults. Neurobiol Aging 1985;6:193–198.
  13. Hartikainen P, Soinen H, Partanen J, Helkala EL, Riekkinen P: Aging and spectral analysis of EEG in normal subjects: A link to memory and CSF AChE. Acta Neurol Scand 1992;86:148–155.
  14. Szelies B: Brain Mapping zur Darstellung altersabhängiger Veränderungen in Abgrenzung von Demenz. Nervenarzt 1992;63:609–618.
  15. Coben LA, Danzinger W, Storandt M: A longitudinal EEG study of mild senile dementia of Alzheimer type: Changes at 1 year and at 2.5 years. Electroencephalogr Clin Neurophysiol 1985;61:101–112.
  16. Dierks T, Perisic I, Frölich L, Ihl R, Maurer K: Topography of the quantitative electroencephalogram in dementia of the Alzheimer type: Relation to severity of dementia. Psychiatr Res 1991;40:181–194.
  17. Müller TJ, Thome J, Chiaramonti R, Dierks T, Maurer K, Fallgatter AJ, Frölich L, Scheubeck M, Strik WK: A comparison of qEEG and HMPAO-SPECT in relation to the clinical severity of Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci 1997;247:259–263.
  18. Buchan RJ, Nagata K, Yokoyama E, Langman P, Yuya H, Hirata Y, Hatazawa J, Kanno I: Regional correlations between the EEG and oxygen metabolism in dementia of Alzheimer’s type. Electroencephalogr Clin Neurophysiol 1997;103:409–417.
  19. Ihl R, Dierks T, Martin E-M, Frölich L, Maurer K: Topography of the maximum of the amplitude of EEG frequency bands in dementia of the Alzheimer type. Biol Psychiatry 1996;39:319–325.
  20. Bartus RT, Dean RL, Beer B, Lippa AS: The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;17:408–417.
  21. Davies P, Maloney JF: Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 1976;ii:403.
  22. Riekkinen P, Buzsaki G, Riekkinen P Jr, Soininen H, Partanen J: The cholinergic system and EEG slow waves. Electroencephalogr Clin Neurophysiol 1991;78:89–96.
  23. Kikuchi M, Wada Y, Nanbu Y, Nakajima A, Tachibana H, Takeda T, Hashimoto T: EEG changes following scopolamine administration in healthy subjects. Neuropsychobiology 1999;39:219–226.
  24. Agnoli A, Martucci N, Manna V, Conti L, Fioravanti M: Effect of cholinergic and anticholinergic drugs on short-term memory in Alzheimer’s dementia: A neuropsychological and computerized electroencephalographic study. Clin Neuropharmacol 1983;6:311–323.

    External Resources

  25. Alhainen K, Riekkinen PJ: Discrimination of Alzheimer patients responding to cholinesterase inhibitor therapy. Acta Neurol Scan 1993;149(suppl):16–21.
  26. Gustafson L, Edvinsson L, Dahlgren N, et al: Intravenous physostigmine treatment of Alzheimer’s disease evaluated by psychometric testing, regional cerebral blood flow measurement, and EEG. Psychopharmacology 1987;93:31–35.

    External Resources

  27. Jelic V, Dierks T, Amberla K, Almkvist O, Winblad B, Nordberg A: Longitudinal changes in quantitative EEG during long-term tacrine treatment of patients with Alzheimer’s disease. Neurosci Lett 1998;254:85–88.

    External Resources

  28. Minthon L, Gustafson L, Dalfelt G, Hagberg B, Nilsson K, Risberg J, Rosén I, Seiving B, Wendt PE: Oral tetrahydroaminoacridine treatment of Alzheimer’s disease evaluated clinically and by regional cerebral blood flow and EEG. Dementia 1993;4:32–42.
  29. Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P: Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: International, randomised controlled trial. BMJ 1999;318:633–640.
  30. Folstein MF, Folstein SE, McHugh PR: ‘Mini mental state’: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  31. Reisberg B, Ferris SH, de Leon MJ, Crook T: The global deterioration scale of assessment of primary degenerative dementia. Am J Psychiat 1982;139:1136–1139.
  32. Katznelson RD (1981): EEG recording, electrode placement, and aspects of generator localization; in Nuñez PL (ed): Electrical fields of the brain. New York, Oxford University Press, 1981.
  33. Semlitsch HV, Anderer P, Saletu B, Schuster P, Presslich O: A solution for reliable and valid reduction of ocular artifacts to the P300 ERP. Psychophysiology 1986;23:695–703.

Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00